Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma

被引：19

作者：

O'Donnell, Elizabeth K. ^{[1
]}

Laubach, Jacob P. ^{[2
]}

Yee, Andrew J. ^{[1
]}

Redd, Robert ^{[3
]}

Huff, Carol Ann ^{[4
]}

Basile, Frank ^{[5
]}

Wade, Philip M. ^{[6
]}

Paba-Prada, Claudia E. ^{[3
]}

Ghobrial, Irene M. ^{[7
]}

Schlossman, Robert L. ^{[2
]}

Burke, Jill N. ^{[1
]}

Harrington, Cynthia C. ^{[1
]}

Lively, Kathleen J. ^{[1
]}

Lyons, Hannah ^{[8
]}

Munshi, Nikhil C. ^{[3
]}

Anderson, Kenneth C. ^{[9
]}

Richardson, Paul G. ^{[3
]}

Raje, Noopur S. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[2] Harvard Med Sch, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[5] Cape Cod Hosp, Cambridge, MA USA

[6] Cape Cod Hosp, Hyannis, MA USA

[7] Harvard Med Sch, Boston, MA 02115 USA

[8] Mass Gen North Shore Canc Ctr, Danvers, MA USA

[9] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1182/blood-2019-128000

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3178

引用

页数：3